TSHA vs VRTX vs REGN vs SRPT

For growth investors, Taysha Gene Therapies, Inc.

(TSHA) is the stronger pick with 17. 3% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Taysha Gene Therapies, Inc. (TSHA) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Regeneron Pharmaceuticals, Inc.

(REGN) is the cheapest at 17. 1x versus Vertex Pharmaceuticals Incorporated at 27. 7x. On forward P/E, Sarepta Therapeutics, Inc. is actually cheaper at 6. 9x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Regeneron Pharmaceuticals, Inc. wins at 2. 43x versus Vertex Pharmaceuticals Incorporated's 2. 68x.

Over the past 5 years, Vertex Pharmaceuticals Incorporated (VRTX) delivered a total return of +97.

7%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: VRTX returned +382. 6% versus TSHA's -72. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 81β versus Taysha Gene Therapies, Inc. 's 2. 06β — meaning TSHA is approximately 155% more volatile than REGN relative to the S&P 500. On balance sheet safety, Taysha Gene Therapies, Inc. (TSHA) carries a lower debt/equity ratio of 7% versus 91% for Sarepta Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Taysha Gene Therapies, Inc.

(TSHA) is pulling ahead at 17. 3% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: Vertex Pharmaceuticals Incorporated grew EPS 836. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, TSHA leads at 57. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Vertex Pharmaceuticals Incorporated (VRTX) is the more profitable company, earning 32.

7% net margin versus -1115. 3% for Taysha Gene Therapies, Inc. — meaning it keeps 32. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VRTX leads at 39. 4% versus -1130. 6% for TSHA. At the gross margin level — before operating expenses — TSHA leads at 88. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Regeneron Pharmaceuticals, Inc. (REGN) is the more undervalued stock at a PEG of 2. 43x versus Vertex Pharmaceuticals Incorporated's 2. 68x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Sarepta Therapeutics, Inc. (SRPT) trades at 6. 9x forward P/E versus 22. 2x for Vertex Pharmaceuticals Incorporated — 15. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TSHA: 67. 5% to $11. 17.

In this comparison, REGN (0.

5% yield) pays a dividend. TSHA, VRTX, SRPT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Vertex Pharmaceuticals Incorporated (VRTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

82), +382. 6% 10Y return). Taysha Gene Therapies, Inc. (TSHA) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VRTX: +382. 6%, TSHA: -72. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TSHA is a small-cap high-growth stock; VRTX is a mid-cap quality compounder stock; REGN is a mid-cap deep-value stock; SRPT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.